Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Add To Watchlist

Recent & Breaking News (NDAQ:HALO)

Halozyme to Host Second Quarter 2015 Financial Results Conference Call

PR Newswire August 3, 2015

Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer

PR Newswire July 31, 2015

Eisai and Halozyme Sign Collaboration Agreement to Investigate Halaven® (Eribulin) and PEGPH20 in Metastatic Breast Cancer

PR Newswire July 30, 2015

Halozyme Therapeutics To Present At The JMP Securities 2015 Life Sciences Conference

PR Newswire June 19, 2015

Halozyme Announces Plans For CFO Transition, Names Laurie Stelzer CFO

PR Newswire June 5, 2015

Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie

PR Newswire June 3, 2015

Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients

PR Newswire May 31, 2015

Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment

PR Newswire May 27, 2015

Halozyme Therapeutics To Present At The UBS 2015 Global Health Care Conference

PR Newswire May 12, 2015

Halozyme Reports First Quarter 2015 Financial Results

PR Newswire May 11, 2015

Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference

PR Newswire May 7, 2015

Halozyme To Host First Quarter 2015 Financial Results Conference Call

PR Newswire May 4, 2015

Halozyme Therapeutics Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel And Chief Compliance Officer

PR Newswire April 13, 2015

Halozyme Provides Update Following Type B FDA Meeting

PR Newswire April 8, 2015

Halozyme Therapeutics Appoints James Mazzola To Lead Corporate Communications, Investor Relations

PR Newswire March 23, 2015

Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer

PR Newswire March 18, 2015

Halozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration

PR Newswire March 10, 2015

Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference

PR Newswire March 3, 2015

Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results

PR Newswire March 2, 2015

Halozyme to Host Fourth Quarter and 2014 Year-End Financial Results Conference Call

PR Newswire February 23, 2015